XERS
NASDAQ HealthcareXeris Biopharma Holdings, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
๐ Market Data
| Price | $8.52 |
|---|---|
| Volume | 1,334,832 |
| Market Cap | 1.55B |
| Beta | 0.850 |
| RSI (14-Day) | 54.5 |
| 200-Day MA | $7.03 |
| 50-Day MA | $7.90 |
| 52-Week High | $10.08 |
| 52-Week Low | $5.25 |
| Forward P/E | 21.85 |
| Price / Book | 103.90 |
๐ฏ Investment Strategy Scores
XERS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (47/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (32/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find XERS in your text
Paste any article, transcript, or post โ the tool will extract XERS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.